Abstract Search

ea0099p450 | Calcium and Bone | ECE2024

A pharmacoeconomic analysis from Italian guidelines for the management of sporadic primary hyperparathyroidism

Attanasio Roberto Samperi Irene , Scoppola Alessandro , Paoletta Agostino , Novizio Roberto , Vescini Fabio , Borretta Giorgio , Chiodini Iacopo , Papini Enrico , Persichetti Agnese , Basile Michele , Boniardi Marco , Carotti Marina , Castellano Elena , Cipriani Cristiana , Eller-Vainicher Cristina , Giannini Sandro , Iacobone Maurizio , Salcuni Antonio/////Stefano , Saponaro Federica , Spiezia Stefano , Versari Annibale , Zavatta Guido , Mitrova Zuzana , Giovannazzi Alexia , Saulle Rosella , Vecchi Simona , Antonini Debora , Calo Giorgio , Cetani Filomena , Cianferotti Luisella , Corbetta Sabrina , De Rimini Maria Luisa , Falchetti Alberto , Iannetti Giovanni , Laureti Stefano , Lombardi Celestino/////Pio , Madeo Bruno , Marcocci Claudio , Mazzaferro Sandro , Miele Vittorio , Minisola Salvatore , Palermo Andrea , Pepe Jessica , Tonzar Laura , Scillitani Alfredo , Grimaldi Franco , Cozzi Renato , Attanasio Roberto

Background: Primary hyperparathyroidism (PHPT) is the third most common endocrine disease and the most frequent cause of hypercalcemia in outpatients with an estimated incidence of 20/100 000/year and prevalence in the general population of 0.1%0.4%. Parathyroidectomy (PTX) is the only treatment that can achieve PHPT cure but a few medications can be used to control calcium levels, bone and kidney impairment.Aims: 1) To assess costs associated with...

0 shares

Endocrine Abstracts

A pharmacoeconomic analysis from Italian guidelines for the management of sporadic primary hyperparathyroidism

BiosciAbstracts